ANN ARBOR, MI / ACCESSWIRE / April 9, 2018 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, has been invited to demonstrate its Nexus-128+ preclinical research instrument at the AACR Annual Meeting 2018 being held on April 14-18, 2018 at McCormick Place in Chicago.

ENDRA will showcase its latest photoacoustic computed tomography system, the Nexus 128+, with proprietary 3D imaging technology in Booth #3446. For a full list of exhibitors, click here.

The Nexus 128 has become a valuable research tool for studying in vivo mouse models of oncologic disease. It combines the most compelling features of optical imaging and ultrasound to form images with both high optical contrast and high ultrasound resolution at depth. Various endogenous and exogenous absorbers can serve as photoacoustic contrast agents, which enables the visualization and quantification of tumor vasculature, volume, tumor heterogeneity, oxygen saturation, hemoglobin concentration, as well as tumor-targeting molecular probes and putative therapeutic agents.

The Nexus 128+ is equipped with a unique rotating hemispherical array of ultrasound transducers which enables it to acquire complete 3D volumetric image sets in as little as three seconds. As such, The Nexus 128+ is particularly well suited for studying the uptake/perfusion of exogenous, tumor-targeting compounds over time, with exceptional spatial and temporal resolution.

"ENDRA's development of preclinical photoacoustic CT scanners used by global research scientists underscores our commitment to commercializing leading edge tools, and our plan to bring to market a disruptive technology for the clinical market in 2018," said Francois Michelon, ENDRA's CEO.

"By leveraging our experience with Nexus 128+ technology, ENDRA is developing a more powerful Thermo-Acoustic Enhanced UltraSound, TAEUS™, for clinical use. Substituting radio frequencies for the near-infrared light of Nexus 128, we've created a system that can overlay new information on conventional ultrasound - showing tissue temperature, composition, vasculature and perfusion in real time," concluded Michelon.

About American Association for Cancer Research

The AACR is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attract the premier researchers in the field. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer. For more information, click here.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA) is a developer of enhanced ultrasound technologies. ENDRA's Photo-Acoustic Nexus-128 system is currently used by leading global medical researchers to screen and modify disease models with high image quality and volume scanning speed. ENDRA's next generation Thermo-Acoustic Enhanced UltraSound ("TAEUS") will enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only on CT & MRI - at a fraction of the cost, and at the point-of-care. ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally. ENDRA's goal is to bring new capabilities to ultrasound - thereby broadening access to better healthcare. For more information, please visit

Forward-Looking Statements

All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC"), which can be found on the SEC's website at We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Company Contact:

David Wells
Chief Financial Officer
(734) 997-0464

Media & Investor Relations Contact:

MZ North America
Chris Tyson
Managing Director
(949) 491-8235

SOURCE: ENDRA Life Sciences Inc.